Compare ZION & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ZION | TGTX |
|---|---|---|
| Founded | 1873 | 1993 |
| Country | United States | United States |
| Employees | N/A | 399 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4B | 8.5B |
| IPO Year | 2012 | 2008 |
| Metric | ZION | TGTX |
|---|---|---|
| Price | $65.74 | $56.12 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 18 | 5 |
| Target Price | ★ $65.33 | $49.80 |
| AVG Volume (30 Days) | 1.2M | ★ 1.7M |
| Earning Date | 04-20-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.88% | N/A |
| EPS Growth | 21.41 | ★ 1746.67 |
| EPS | ★ 4.61 | 0.17 |
| Revenue | ★ $662,000,000.00 | $2,785,000.00 |
| Revenue This Year | $8.57 | $49.08 |
| Revenue Next Year | $4.67 | $26.69 |
| P/E Ratio | ★ $14.57 | $329.40 |
| Revenue Growth | ★ 3.60 | N/A |
| 52 Week Low | $46.21 | $26.76 |
| 52 Week High | $73.34 | $59.30 |
| Indicator | ZION | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 32.15 | 59.46 |
| Support Level | $58.17 | $51.51 |
| Resistance Level | $66.18 | $58.12 |
| Average True Range (ATR) | 1.48 | 2.21 |
| MACD | -0.18 | -0.03 |
| Stochastic Oscillator | 0.25 | 76.89 |
Zions Bancorp is a US regional bank with around $90 billion in total assets as of Sept. 30, 2025. Headquartered in Salt Lake City, Utah, Zions' branch network is in the Western and Southwestern United States and includes seven affiliate banks in these markets. The bank has a heavy focus on small and midsize commercial banking.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.